Matinas BioPharma (MTNB) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to Matinas BioPharma (MTNB) Reports In-Line Q4 EPS

Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

March 29, 2021 6:30 AM EDT

Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics

Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data of key second patient cohort anticipated Q3 2021

Collaboration with National Institute of Allergy and Infectious Disease (NIAID) to formulate Gileads antiviral COVID-19 medication remdesivir has progressed into in vitro studies

Data from ENHANCE-IT study of LYPDISO against Vascepa® support continued development of LYPDISO as a... More